A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
Public ClinicalTrials.gov record NCT06921759. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose.
Study identification
- NCT ID
- NCT06921759
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 221 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 21, 2025 (Actual)
- Primary completion
- May 13, 2026 (Actual)
- Completion
- Jul 28, 2026 (Actual)
- Last update posted
- Aug 20, 2026
2025 – 2026
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| First OC Dermatology Research Inc | Fountain Valley | California | 92708 | — |
| Dermatology Research Associates | Los Angeles | California | 90045 | — |
| Encore Medical Research | Hollywood | Florida | 33024 | — |
| Research Associates of South Florida - Miami - Southwest 8th Street | Miami | Florida | 33134 | — |
| Renstar Medical Research | Ocala | Florida | 34470 | — |
| DeNova Research | Chicago | Illinois | 60602 | — |
| Southern Indiana Clinical Trials | New Albany | Indiana | 47150 | — |
| Revival Research Institute, LLC | Troy | Michigan | 48084 | — |
| MediSearch Clinical Trials | Saint Joseph | Missouri | 64506 | — |
| Care Access - Hoboken | Hoboken | New Jersey | 07030 | — |
| Optima Research - Boardman | Boardman | Ohio | 44512 | — |
| Progressive Clinical Research | San Antonio | Texas | 78213 | — |
| Texas Dermatology and Laser Specialists | San Antonio | Texas | 78218 | — |
| Complete Dermatology | Sugar Land | Texas | 77479 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06921759, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06921759 live on ClinicalTrials.gov.